These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11468515)

  • 21. Differential expression of tissue inhibitor of matrix metalloproteinases 3 in uveal melanoma.
    Nareyeck G; Zeschnigk M; von der Haar D; Schilling H; Bornfeld N; Anastassiou G
    Ophthalmic Res; 2005; 37(1):23-8. PubMed ID: 15637418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
    Nip J; Rabbani SA; Shibata HR; Brodt P
    J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion.
    Ellerbroek SM; Hudson LG; Stack MS
    Int J Cancer; 1998 Oct; 78(3):331-7. PubMed ID: 9766568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein--a new prognostic marker in uveal melanoma?
    Väisänen A; Kallioinen M; von Dickhoff K; Laatikainen L; Höyhtyä M; Turpeenniemi-Hujanen T
    J Pathol; 1999 May; 188(1):56-62. PubMed ID: 10398141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
    Ahmed N; Pansino F; Baker M; Rice G; Quinn M
    J Cell Biochem; 2002; 84(4):675-86. PubMed ID: 11835393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression.
    Martens JW; Sieuwerts AM; Bolt-deVries J; Bosma PT; Swiggers SJ; Klijn JG; Foekens JA
    Thromb Haemost; 2003 Feb; 89(2):393-404. PubMed ID: 12574821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.
    Montgomery AM; De Clerck YA; Langley KE; Reisfeld RA; Mueller BM
    Cancer Res; 1993 Feb; 53(3):693-700. PubMed ID: 8425205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-10 may participate in regulating trophoblast invasion in human placentae throughout gestation.
    Pang ZJ; Zhou JG; Huang LP
    Am J Reprod Immunol; 2008 Jul; 60(1):19-25. PubMed ID: 18593434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao E; Han D; Yu Z; Fan E; Li Y; Zhou Z
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Nov; 16(11):599-602. PubMed ID: 15515548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
    Gershtein ES; Medvedeva SV; Babkina IV; Kushlinskii NE; Trapeznikov NN
    Bull Exp Biol Med; 2001 Jul; 132(1):670-4. PubMed ID: 11687850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells.
    Girnita A; All-Ericsson C; Economou MA; Aström K; Axelson M; Seregard S; Larsson O; Girnita L
    Acta Ophthalmol; 2008 Nov; 86 Thesis 4():26-34. PubMed ID: 19032679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
    Umeda T; Eguchi Y; Okino K; Kodama M; Hattori T
    J Pathol; 1997 Dec; 183(4):388-97. PubMed ID: 9496254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
    Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
    Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
    Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrin expression in uveal melanoma differs from cutaneous melanoma.
    ten Berge PJ; Danen EH; van Muijen GN; Jager MJ; Ruiter DJ
    Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3635-40. PubMed ID: 8258522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
    Naitoh H; Eguchi Y; Ueyama H; Kodama M; Hattori T
    Jpn J Cancer Res; 1995 Jan; 86(1):48-56. PubMed ID: 7737909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteolysis in human breast cancer.
    Garbett EA; Reed MW; Stephenson TJ; Brown NJ
    Mol Pathol; 2000 Apr; 53(2):99-106. PubMed ID: 10889910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.